Longevity & AgingScribe Therapeutics Wins $25M to Develop One-Shot CRISPR Heart Disease Cures
Scribe Therapeutics has received over $25 million from the California Institute for Regenerative Medicine to advance two CRISPR-based gene therapies targeting inherited cardiovascular risk. The first, STX-1200, aims to permanently reduce lipoprotein(a) — an inherited risk factor for heart attacks affecting roughly one in five people worldwide that diet and exercise cannot meaningfully lower. The second, STX-1400, targets the APOC3 gene to control dangerously high triglycerides, particularly in patients with familial chylomicronemia syndrome who face pancreatitis risk. Both therapies are designed as single-treatment interventions, potentially replacing lifelong medication regimens. The funding will support moving these programs toward clinical trials, representing a significant step in treating common cardiometabolic diseases at their genetic source rather than managing symptoms after damage has already occurred.
